SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-191715
Filing Date
2021-06-16
Accepted
2021-06-16 09:20:29
Documents
5
Period of Report
2021-06-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d113030d8k.htm 8-K 29956
2 EX-1.1 d113030dex11.htm EX-1.1 253983
3 EX-4.1 d113030dex41.htm EX-4.1 115673
4 EX-99.1 d113030dex991.htm EX-99.1 13369
5 GRAPHIC g113030g0615230855112.jpg GRAPHIC 3147
  Complete submission text file 0001193125-21-191715.txt   418621
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 211020599
SIC: 2836 Biological Products, (No Diagnostic Substances)